4-(3-chloro-5-cyclopentyl-4,5-dihydro-1H-pyrazol-1-yl)-2-methylbenzonitrile | 1246765-04-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3-chloro-5-cyclopentyl-4,5-dihydro-1H-pyrazol-1-yl)-2-methylbenzonitrile
• 英文别名: 4-(5-chloro-3-cyclopentyl-3,4-dihydropyrazol-2-yl)-2-methylbenzonitrile
• CAS: 1246765-04-7
• 化学式: C₁₆H₁₈ClN₃
• 分子量: 287.792
• InChiKey: UAKWJKXFCCPVQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-chloro-5-cyclopentyl-4,5-dihydro-1H-pyrazol-1-yl)-2-methylbenzonitrile 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 potassium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 二氧化碳 、 异丙醇 为溶剂， 反应 4.0h， 生成 (R)-methyl 6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinate
  参考文献：
  名称：

  Synthesis and cross coupling of a highly substituted 2-pyridylboronate: application to the large scale synthesis of a mineralocorticoid antagonist

  摘要：

  The large scale synthesis of a functionalized 2-pyridylboronate 8 and optimization of its Suzuki-Miyaura coupling to chloropyrazoline (R)-7 to provide a scalable synthesis of mineralocorticoid antagonist (R)-1 is described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.10.052
• 作为产物：
  描述：

  4-(5-cyclopentyl-3-oxopyrazolidin-1-yl)-2-methylbenzonitrile 在 三氯氧磷 作用下， 以 乙腈 为溶剂， 以89%的产率得到4-(3-chloro-5-cyclopentyl-4,5-dihydro-1H-pyrazol-1-yl)-2-methylbenzonitrile
  参考文献：
  名称：

  Synthesis and cross coupling of a highly substituted 2-pyridylboronate: application to the large scale synthesis of a mineralocorticoid antagonist

  摘要：

  The large scale synthesis of a functionalized 2-pyridylboronate 8 and optimization of its Suzuki-Miyaura coupling to chloropyrazoline (R)-7 to provide a scalable synthesis of mineralocorticoid antagonist (R)-1 is described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.10.052

文献信息

• 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES
  申请人：Arhancet Graciela Barbieri

  公开号：US20120022058A1

  公开（公告）日：2012-01-26

  Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

  矿物质皮质激素受体拮抗剂（MRa），含有这种抑制剂的制药组合物以及使用这种抑制剂治疗哺乳动物（包括人类）中的糖尿病肾病和高血压。
• [EN] 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES<br/>[FR] COMPOSÉS 4,5-DIHYDRO-LH-PYRAZOLE ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：PFIZER

  公开号：WO2010116282A8

  公开（公告）日：2011-11-03
• 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES
  申请人：Pfizer Inc.

  公开号：EP2417121A1

  公开（公告）日：2012-02-15
• [EN] 4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES<br/>[FR] COMPOSÉS 4,5-DIHYDRO-LH-PYRAZOLE ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：PFIZER

  公开号：WO2010116282A1

  公开（公告）日：2010-10-14

  Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.
• [EN] SPIRO-CONTAINING DIHYDROPYRAZOLE COMPOUNDS<br/>[FR] COMPOSÉS DIHYDROPYRAZOLES CONTENANT LE SPIRO
  申请人：KBP BIOSCIENCES CO LTD

  公开号：WO2012126275A1

  公开（公告）日：2012-09-27

  Provided are compounds of formula (I), pharmaceutically acceptable salts, esters, or solvates, or prodrugs or isomers thereof. Thereinto, Cy1, L, X, Y1, Y2, n1, n2, n3, n4, R1a, R1b, R3a, R3b, R4, R5 and m are defined as in the description.